Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis.

Fomivirsen is a 21-nucleotide phosphorothioate oligonucleotide which, when injected into a human eye, is capable of inhibiting CMV retinitis. Its mode of action is consistent with an antisense mechanism. Prior to human trials, fomivirsen was tested in a number of in vitro cell lines and was found to inhibit CMV replication in a dose-dependent manner with a mean 50% inhibitory concentration between 0.03 and 0.2 microM. Intravitreal drug clearance studies have revealed first-order kinetics with a half-life in the rabbit of 62 hours. In a clinical trial of patients with newly diagnosed CMV retinitis receiving 165 mg per injection, time to progression was interpolated to 71 days with 44% of the patients remaining on treatment for over one year. In patients who failed other anti-CMV treatments, the interpolated time to progression was 91 days when receiving 330 mg per injection. No systemic absorption of the drug could be detected. Reported adverse events have been for the most part mild to moderate in intensity and either resolved spontaneously or were treatable with topical medications. Locally administered fomivirsen effectively inhibits CMV retinitis using a mode of action which is complementary to existing DNA polymerase inhibitors.

[1]  D. Ecker,et al.  Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Krieg,et al.  Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. , 1996, Journal of immunology.

[3]  W. H. Barr,et al.  A pharmacokinetic evaluation of 14C‐labeled afovirsen sodium in patients with genital warts , 1994, Clinical pharmacology and therapeutics.

[4]  Y. Cheng,et al.  Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides , 1990, Antimicrobial Agents and Chemotherapy.

[5]  A. Zutshi,et al.  Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[6]  Y. Cheng,et al.  Effect of phosphorothioate homo-oligodeoxynucleotides on herpes simplex virus type 2-induced DNA polymerase. , 1989, The Journal of biological chemistry.

[7]  Matthew T. Davis,et al.  A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. , 1991, Annals of internal medicine.

[8]  C. F. Bennett,et al.  Progress in antisense oligonucleotide therapeutics. , 1996, Annual review of pharmacology and toxicology.

[9]  S. Yamamoto,et al.  Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. , 1994, Antisense research and development.

[10]  C. Katlama,et al.  Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. , 1991, Ophthalmology.

[11]  S. Crooke.  Progress in antisense therapeutics discovery and development. , 1997, Ciba Foundation symposium.

[12]  G. Bishop,et al.  CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.

[13]  Discovering antisense reagents by hybridization of RNA to oligonucleotide arrays. , 1997, Ciba Foundation symposium.

[14]  R. Crooke,et al.  Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region , 1993, Antimicrobial Agents and Chemotherapy.

[15]  S. Crooke,et al.  Effect of antisense oligonucleotides on cytokine release from human keratinocytes in an in vitro model of skin. , 1996, Toxicology and applied pharmacology.

[16]  T. Merigan,et al.  Interferon Induction Increased through Chemical Modification of a Synthetic Polyribonucleotide , 1969, Science.

[17]  P. D. Cook,et al.  Antisense medicinal chemistry , 1998 .

[18]  G. Hartmann,et al.  Oligodeoxynucleotides Enhance Lipopolysaccharide-Stimulated Synthesis of Tumor Necrosis Factor: Dependence on Phosphorothioate Modification and Reversal by Heparin , 1996, Molecular medicine.

[19]  K U Mir,et al.  Arrays of complementary oligonucleotides for analysing the hybridisation behaviour of nucleic acids. , 1994, Nucleic acids research.

[20]  A. Levin,et al.  Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[21]  A. Levin,et al.  Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. , 1997, Antisense & nucleic acid drug development.

[22]  Immune Stimulation by Oligonucleotides , 1998 .

[23]  J. P. Shea,et al.  Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. , 1993, The Journal of pharmacology and experimental therapeutics.

[24]  S. Beaucage,et al.  CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Kornbrust,et al.  Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats. , 1997, Toxicology.

[26]  R. Buckheit,et al.  Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. , 1995, Antiviral research.

[27]  D. Hume,et al.  Macrophages ingest and are activated by bacterial DNA. , 1996, Journal of immunology.

[28]  M. Stephenson,et al.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.